company background image
ZYME

Zymeworks NYSE:ZYME Stock Report

Last Price

US$6.30

Market Cap

US$364.0m

7D

3.3%

1Y

-83.0%

Updated

26 Jun, 2022

Data

Company Financials +
ZYME fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ZYME Stock Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer.

Zymeworks Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Zymeworks
Historical stock prices
Current Share PriceUS$6.30
52 Week HighUS$39.41
52 Week LowUS$4.56
Beta1.05
1 Month Change-1.10%
3 Month Change-10.00%
1 Year Change-82.96%
3 Year Change-71.36%
5 Year Change-24.55%
Change since IPO-51.54%

Recent News & Updates

May 17

Zymeworks And The Blue Falcon Elucidation

Zymeworks shares have fallen, but the pipeline remains intact. Moreover, a special situation is brewing. Positive expectation with ZYME.

Shareholder Returns

ZYMEUS BiotechsUS Market
7D3.3%10.3%6.6%
1Y-83.0%-24.3%-18.4%

Return vs Industry: ZYME underperformed the US Biotechs industry which returned -24.4% over the past year.

Return vs Market: ZYME underperformed the US Market which returned -18.5% over the past year.

Price Volatility

Is ZYME's price volatile compared to industry and market?
ZYME volatility
ZYME Average Weekly Movement15.0%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.6%
10% least volatile stocks in US Market3.2%

Stable Share Price: ZYME is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: ZYME's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2003327Ken Galbraithhttps://www.zymeworks.com

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company’s lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Zymeworks Fundamentals Summary

How do Zymeworks's earnings and revenue compare to its market cap?
ZYME fundamental statistics
Market CapUS$363.96m
Earnings (TTM)-US$239.88m
Revenue (TTM)US$27.95m

13.0x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ZYME income statement (TTM)
RevenueUS$27.95m
Cost of RevenueUS$217.74m
Gross Profit-US$189.79m
Other ExpensesUS$50.09m
Earnings-US$239.88m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.15
Gross Margin-678.98%
Net Profit Margin-858.18%
Debt/Equity Ratio0%

How did ZYME perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ZYME undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ZYME?

Other financial metrics that can be useful for relative valuation.

ZYME key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.4x
Enterprise Value/EBITDA-0.4x
PEG Ration/a

Price to Sales Ratio vs Peers

How does ZYME's PS Ratio compare to its peers?

ZYME PS Ratio vs Peers
The above table shows the PS ratio for ZYME vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average82.8x

Price-To-Sales vs Peers: ZYME is good value based on its Price-To-Sales Ratio (13x) compared to the peer average (82.8x).


Price to Earnings Ratio vs Industry

How does ZYME's PE Ratio compare vs other companies in the U.S. Biotechs Industry?

Price-To-Sales vs Industry: ZYME is good value based on its Price-To-Sales Ratio (13x) compared to the US Biotechs industry average (14.1x)


Price to Sales Ratio vs Fair Ratio

What is ZYME's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ZYME PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio13x
Fair PS Ratio0.006x

Price-To-Sales vs Fair Ratio: ZYME is expensive based on its Price-To-Sales Ratio (13x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Share Price vs Fair Value

What is the Fair Price of ZYME when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ZYME's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ZYME's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ZYME's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Zymeworks forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

Future Growth Score

2/6

Future Growth Score 2/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZYME is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZYME is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZYME is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ZYME's revenue (51.2% per year) is forecast to grow faster than the US market (8.4% per year).

High Growth Revenue: ZYME's revenue (51.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ZYME is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has Zymeworks performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-44.7%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ZYME is currently unprofitable.

Growing Profit Margin: ZYME is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ZYME is unprofitable, and losses have increased over the past 5 years at a rate of 44.7% per year.

Accelerating Growth: Unable to compare ZYME's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZYME is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).


Return on Equity

High ROE: ZYME has a negative Return on Equity (-84.93%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Zymeworks's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ZYME's short term assets ($324.0M) exceed its short term liabilities ($80.0M).

Long Term Liabilities: ZYME's short term assets ($324.0M) exceed its long term liabilities ($67.6M).


Debt to Equity History and Analysis

Debt Level: ZYME is debt free.

Reducing Debt: ZYME has no debt compared to 5 years ago when its debt to equity ratio was 8.8%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZYME has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ZYME has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 45.4% each year.


Discover healthy companies

Dividend

What is Zymeworks's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ZYME's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ZYME's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ZYME's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZYME's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ZYME has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

0.4yrs

Average management tenure


CEO

Ken Galbraith (58 yo)

0.42

Tenure

US$166,711

Compensation

Mr. Kenneth H. Galbraith, also known as Ken, C.A., serves as Chief Executive Officer & Chairman of the Board at Zymeworks Inc since January 15, 2022 and serves as its President since January 15, 2022. He s...


Leadership Team

Experienced Management: ZYME's management team is not considered experienced ( 0.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: ZYME's board of directors are considered experienced (3.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ZYME insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 25.1%.


Top Shareholders

Company Information

Zymeworks Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Zymeworks Inc.
  • Ticker: ZYME
  • Exchange: NYSE
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$363.959m
  • Shares outstanding: 57.77m
  • Website: https://www.zymeworks.com

Number of Employees


Location

  • Zymeworks Inc.
  • 114 East 4th Avenue
  • Suite 800
  • Vancouver
  • British Columbia
  • V5T 1G4
  • Canada

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/26 00:00
End of Day Share Price2022/06/24 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.